This grant opportunity from the Food and Drug Administration focuses on the synthesis and biological activity assessment of different diastereomers in the siRNA drug LEQVIO (Inclisiran). Clinical trials are not allowed under this funding. The deadline for applications is May 19, 2026. No further details or eligibility criteria are provided.
Eligibility details not specified in the grant listing. Contact the Food and Drug Administration for requirements.
